亚洲一区二区三区看片,日韩欧美九九九久久久,精品国产日韩亚洲一区在线,久久噜噜噜久久熟女精品

掃碼關(guān)注公眾號(hào)           掃碼咨詢技術(shù)支持           掃碼咨詢技術(shù)服務(wù)
  
客服熱線:400-901-9800  客服QQ:4009019800  技術(shù)答疑  技術(shù)支持  質(zhì)量反饋  人才招聘  關(guān)于我們  聯(lián)系我們
69影视人妻少妇久久中文字幕,欧美日韩欧美日韩欧美日韩欧美日韩,国产精品无码无在线观看
Rabbit Anti-EpCAM/APC Conjugated antibody (bs-1513R-APC)
訂購(gòu)熱線:400-901-9800
訂購(gòu)郵箱:sales@www.lalhoau.cn
訂購(gòu)QQ:  400-901-9800
技術(shù)支持:techsupport@www.lalhoau.cn
說(shuō) 明 書(shū): 100ul  
100ul/2980.00元
大包裝/詢價(jià)
產(chǎn)品編號(hào) bs-1513R-APC
英文名稱1 Rabbit Anti-EpCAM/APC Conjugated antibody
中文名稱 APC標(biāo)記的上皮細(xì)胞粘附分子抗體
別    名 Adenocarcinoma associated antigen; CD326; CD326 antigen; Cell surface glycoprotein Trop 1; CO17 1A; EGP; EGP40; Ep CAM; Epithelial cell surface antigen; Epithelial cellular adhesion molecule; Epithelial glycoprotein; GA733 2; hEGP 2; KS 1/4 antigen; KSA; Lymphocyte antigen 74; M1S2; M4S1; Major gastrointestinal tumor associated protein GA733 2; MIC18; MK 1; TACD1; TACSTD1; TROP1; Tumor associated calcium signal transducer 1.  
規(guī)格價(jià)格 100ul/2980元 購(gòu)買        大包裝/詢價(jià)
說(shuō) 明 書(shū) 100ul  
研究領(lǐng)域 腫瘤  細(xì)胞生物  免疫學(xué)  細(xì)胞粘附分子  細(xì)胞表面分子  
抗體來(lái)源 Rabbit
克隆類型 Polyclonal
交叉反應(yīng) Human, Mouse,  (predicted: Rat, )
產(chǎn)品應(yīng)用 Flow-Cyt=1:50-200 IF=1:50-200 
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量 35kDa
性    狀 Lyophilized or Liquid
濃    度 1mg/ml
免 疫 原 KLH conjugated synthetic peptide derived from human EpCAM
亞    型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
產(chǎn)品介紹 background:
This gene encodes a carcinoma-associated antigen and is a member of a family that includes at least two type I membrane proteins. This antigen is expressed on most normal epithelial cells and gastrointestinal carcinomas and functions as a homotypic calcium-independent cell adhesion molecule. The antigen is being used as a target for immunotherapy treatment of human carcinomas. Mutations in this gene result in congenital tufting enteropathy. [provided by RefSeq, Dec 2008]

Function:
May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E.

Subunit:
Monomer. Interacts with phosphorylated CLDN7.

Subcellular Location:
Lateral cell membrane; Single-pass type I membrane protein. Cell junction, tight junction. Note=Co-localizes with CLDN7 at the lateral cell membrane and tight junction.

Tissue Specificity:
Highly and selectively expressed by undifferentiated rather than differentiated embryonic stem cells (ESC). Levels rapidly diminish as soon as ESC's differentiate (at protein levels). Expressed in almost all epithelial cell membranes but not on mesodermal or neural cell membranes. Found on the surface of adenocarcinoma.

Post-translational modifications:
Hyperglycosylated in carcinoma tissue as compared with autologous normal epithelia. Glycosylation at Asn-198 is crucial for protein stability.

DISEASE:
Defects in EPCAM are the cause of diarrhea type 5 (DIAR5) [MIM:613217]. It is an intractable diarrhea of infancy characterized by villous atrophy and absence of inflammation, with intestinal epithelial cell dysplasia manifesting as focal epithelial tufts in the duodenum and jejunum. Defects in EPCAM are a cause of hereditary non-polyposis colorectal cancer type 8 (HNPCC8) [MIM:613244]. HNPCC is a disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, HNPCC is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. Note=HNPCC8 results from heterozygous deletion of 3-prime exons of EPCAM and intergenic regions directly upstream of MSH2, resulting in transcriptional read-through and epigenetic silencing of MSH2 in tissues expressing EPCAM.

Similarity:
Belongs to the EPCAM family.
Contains 1 thyroglobulin type-1 domain.

Database links:

Entrez Gene: 4072 Human

Entrez Gene: 17075 Mouse

Entrez Gene: 171577 Rat

Omim: 185535 Human

SwissProt: P16422 Human

SwissProt: Q99JW5 Mouse

SwissProt: O55159 Rat

Unigene: 542050 Human

Unigene: 4259 Mouse

Unigene: 106481 Rat



Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
版權(quán)所有 2004-2026 www.www.lalhoau.cn 北京博奧森生物技術(shù)有限公司
通過(guò)國(guó)際質(zhì)量管理體系ISO 9001:2015 GB/T 19001-2016    證書(shū)編號(hào): 00124Q34771R2M/1100
通過(guò)國(guó)際醫(yī)療器械-質(zhì)量管理體系ISO 13485:2016 GB/T 42061-2022    證書(shū)編號(hào): CQC24QY10047R0M/1100
京ICP備05066980號(hào)-1         京公網(wǎng)安備110107000727號(hào)
乐山市| 百色市| 夏邑县| 和顺县| 剑阁县| 兖州市| 民和| 辽阳县| 福鼎市| 景泰县| 封开县| 西和县| 平和县| 蓬安县| 青州市| 阜新| 乌鲁木齐市| 贺兰县| 鄂伦春自治旗| 楚雄市| 安庆市| 行唐县| 名山县| 云和县| 林甸县| 栾城县| 江孜县| 衡阳市| 毕节市| 辉南县| 胶南市| 东明县| 嫩江县| 枣强县| 瑞金市| 尼木县| 安新县| 内丘县| 黄梅县| 禄劝| 白水县|